Soluble expression of recombinant coagulation factor IX protein using Escherichia coli
- PMID: 38681671
- PMCID: PMC11052911
- DOI: 10.1016/j.bbrep.2024.101714
Soluble expression of recombinant coagulation factor IX protein using Escherichia coli
Abstract
Hemophilia B is a congenital bleeding disorder caused by factor IX (FIX) deficiency. Generation of recombinant FIX (rFIX) is required for detecting a Hemophilia B indicator, anti-FIX antibody. In this study, we described a method for producing recombinant FIX (rFIX) using Escherichia coli. We constructed a FIX-expressing plasmid without a fusion tag protein-encoding gene and produced rFIX as a soluble form within five days. Dose-dependent curve was obtained from ELISA using anti-FIX antibody, indicating that the rFIX can be used as an antigen to detect anti-FIX antibody with high affinity and sensitivity.
Keywords: Escherichia coli; Factor IX; Hemophilia; Protein expression; Recombinant protein.
© 2024 The Authors.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures




Similar articles
-
Discovery of An Orally Effective Factor IX-Transferrin Fusion Protein for Hemophilia B.Int J Mol Sci. 2019 Dec 18;21(1):21. doi: 10.3390/ijms21010021. Int J Mol Sci. 2019. PMID: 31861459 Free PMC article.
-
Real-World Use of Albutrepenonacog Alfa, A Recombinant Coagulation Factor IX Albumin Fusion Protein, for Personalized Prophylaxis in Japanese Individuals With Hemophilia B: A Case Series.Cureus. 2023 Jan 9;15(1):e33573. doi: 10.7759/cureus.33573. eCollection 2023 Jan. Cureus. 2023. PMID: 36779089 Free PMC article.
-
In vivo intranasal delivery of coagulation factor IX: a proof-of-concept study.J Thromb Haemost. 2023 Nov;21(11):3117-3123. doi: 10.1016/j.jtha.2023.08.019. Epub 2023 Aug 25. J Thromb Haemost. 2023. PMID: 37633640
-
Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.J Med Econ. 2017 Apr;20(4):337-344. doi: 10.1080/13696998.2016.1265973. Epub 2016 Dec 21. J Med Econ. 2017. PMID: 27885871
-
[Factor IX assays in treated hemophilia B patients].Ann Biol Clin (Paris). 2019 Feb 1;77(1):41-52. doi: 10.1684/abc.2019.1414. Ann Biol Clin (Paris). 2019. PMID: 30799297 Review. French.
References
-
- Lin S.W., Dunn J.J., Studier F.W., Stafford D.W. Expression of human factor IX and its subfragments in Escherichia coli and generation of antibodies to the subfragments. Biochemistry. 1987;26:5267–5274. - PubMed
-
- Lee Y., Hur H., Kim M. Cloning and expression of human clotting factor 9 cDNA in Escherichia coli. Biomedical Science Letters. 1996;2:231–240.
-
- DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br. J. Haematol. 2007;138:305–315. - PubMed
-
- Qing G., Ma L.C., Khorchid A., Swapna G.V., Mal T.K., Takayama M.M., Xia B., Phadtare S., Ke H., Acton T., Montelione G.T., Ikura M., Inouye M. Cold-shock induced high-yield protein production in Escherichia coli. Nat. Biotechnol. 2004;22:877–882. - PubMed
LinkOut - more resources
Full Text Sources